Dtsch Med Wochenschr 2013; 138(14): 703-706
DOI: 10.1055/s-0032-1332995
Hämatologie und Onkologie | Commentary
Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Metastasiertes Prostatakarzinom: Neue Erkenntnisse und Entwicklungen

Metastatic prostate cancer: new insights and developments
A. Lorch
1   Bereich Konservative Urologische Onkologie, Klinik für Urologie, Universitätsklinikum Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
26 March 2013 (online)

    Permissions and Reprints

Schlüsselwörter

Prostatakarzinom - Hormontherapie - Androgendeprivation - Chemotherapie - kastrationsresistent

Keywords

prostate cancer - hormone therapy - androgen deprivation therapy - chemotherapy - castration resistant
 

  • Literatur

  • 1 de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154
    CrossrefGoogle Scholar
  • 2 Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistentprostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822
    CrossrefGoogle Scholar
  • 3 Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992
    CrossrefGoogle Scholar
  • 4 Hussain M, Tangen CM, Higano C et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. J Clin Oncol 2012; 30 Suppl (Suppl. 01) Abstract 4
    Google Scholar
  • 5 Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422
    CrossrefPubMedGoogle Scholar
  • 6 Parker C, Heinrich D, O'Sullivan JM et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 2012; 30 Suppl. (Suppl. 05) Abstract 8
    Google Scholar
  • 7 Logothetis CJ, Basch E, Molina A et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13: 1210-1217
    CrossrefGoogle Scholar
  • 8 Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-583
    CrossrefGoogle Scholar
  • 9 Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520
    CrossrefGoogle Scholar
  • 10 Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148
    CrossrefGoogle Scholar
  • 11 Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197
    CrossrefGoogle Scholar
  • 12 Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512
    CrossrefGoogle Scholar